undamentalytics Newsletter

Cox Kevin Brian: insider trades

Chief executive at Surgepays, Inc. 13 open-market purchases and no sales not made under a pre-set plan, reported from October 28, 2020 to May 19, 2025.

Would copying Cox Kevin Brian’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 1 purchase has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on August 17, 2023 into $6,061 by November 2, 2026, −14.5% a year. The copy held shares only 27% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $14,214, +11.6% a year (the S&P 500 held throughout made $18,042, +20.3% a year). Beta against the index was 0.30. Twelve months after each report, the average purchase was −93.5% against the S&P 500 (median −93.5%), and 0% beat it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$10.0k$20.0k 2023202420252026 $18.0k$14.2k$6.1k
Copying Cox Kevin BrianS&P 500, same days investedS&P 500, held throughout $10,000 copying Cox Kevin Brian’s open-market purchases from August 17, 2023, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−14.5%
S&P 500, same days invested
+11.6% (held throughout +20.3%)
Time in shares
27%
Sharpe ratio (S&P 500)
−0.26 (1.00)
Biggest drop (S&P 500)
−68% (−19%)
Market sensitivity (beta)
0.30
Purchases copied
1

Trade by trade

Cox Kevin Brian: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 1 −2.0% −2.0% 0% 1 — — Not enough years
Purchases, 6 months after the report 1 +34.7% +34.7% 100% 1 — — Not enough years
Purchases, 12 months after the report 1 −93.5% −93.5% 0% 1 — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Surgepays, Inc. SURG CEO and Chairman of Board130October 28, 2020May 19, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 19, 2025May 16, 2025 SURG Purchase $41,451 not yetnot yetnot yet
August 16, 2023August 15, 2023 SURG Purchase $24,544 −2.0%−93.5%not yet
September 1, 2022August 31, 2022 SURG Purchase $21,500 not yetnot yetnot yet
August 19, 2022August 18, 2022 SURG Purchase $33,360 not yetnot yetnot yet
June 3, 2022June 2, 2022 SURG Purchase $21,511 not yetnot yetnot yet
September 14, 2021September 9, 2021 SURG Purchase $50,000 not yetnot yetnot yet
March 1, 2021February 24, 2021 SURG Purchase $19,200 not yetnot yetnot yet
January 11, 2021December 28, 2020 SURG Purchase $20,343 not yetnot yetnot yet
December 7, 2020December 4, 2020 SURG Purchase $15,000 not yetnot yetnot yet
November 13, 2020November 10, 2020 SURG Purchase $19,446 not yetnot yetnot yet
November 4, 2020November 4, 2020 SURG Purchase $12,605 not yetnot yetnot yet
October 30, 2020October 27, 2020 SURG Purchase $25,000 not yetnot yetnot yet
October 28, 2020October 22, 2020 SURG Purchase $12,680 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Cox Kevin Brian traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.